All News

As part of her continuing conversation with PharmExec, Trialynx CEO Angela Schwab goes into detail the importance of understanding a site’s abilities during the development stage of a trial.

In today’s Pharmaceutical Executive Daily, Johnson & Johnson reaches an agreement with the Trump administration while continuing its $55 billion U.S. investment plan, Bristol Myers Squibb outlines its long-term strategic focus at JPMorgan 2026, and Pfizer details its pivot from COVID-era products toward pipeline execution.

Pfizer entered the 44th Annual J.P. Morgan Healthcare Conference emphasizing its post-Covid reset, improved cost discipline, and a catalyst-heavy pipeline aimed at navigating the patent cycle and reaccelerating growth into 2026 and beyond.

Johnson & Johnson reinforces its long-term domestic investment strategy with a new $2 billion biologics facility in Wilson, North Carolina, further elevating the state’s role as a global life sciences hub.

CEO Christopher Boerner detailed the company’s plan to grow ahead of 2030.

Michael O' Rourke , CEO Re-Vana Therapeutics, discusses positioning Re-Vana as a long-term platform partner by leveraging its sustained-delivery hydrogel technologies to support both internally developed assets and external pharma collaborations.

Angela Schwab, founder and CEO of Trialynx, discusses the importance of designing trials around patients and how doing so doesn’t have to come at the cost of generating good data.

Hayley Burgess SVP, Inovalon, touches on Specialty pharmacies grappling with surging drug complexity and costs while navigating fragmented data systems, access hurdles, and prior authorization demands that strain pharmacists’ abilities.

Johnson & Johnson reached a voluntary agreement with the U.S. government to enhance patient access, lower drug costs, and expand domestic manufacturing.

In the third part of her conversation with PharmExec, Trialynx founder and CEO Angela Schwab discusses the causes and solutions for high failure rates in clinical trials.

A new unified approach to process analytical technologies from Recipharm Advanced Bio aims to replace fragmented, off-line testing with integrated real-time analytics—cutting development and release timelines by up to 50% while aligning with FDA-backed continuous manufacturing initiatives and a multibillion-dollar global PAT market opportunity.

Clarivate’s Drugs to Watch 2026 report highlights Eli Lilly’s late-stage cardiometabolic candidates orforglipron and retatrutide as the clear standouts in an obesity and diabetes market projected to reach $150 billion by 2035.

In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry leaders examine how humans and AI can jointly create value in pharma, and Eli Lilly enters a billion-dollar agreement to acquire Ventyx Biosciences.

FDA’s decision to withhold approval of Hetlioz for jet lag disorder underscores the agency’s continued insistence on real-world relevance in clinical evidence.

Lilly’s acquisition of Ventyx deepens its inflammation-focused pipeline with a strategic push to secure differentiated oral therapies aimed at chronic, immune-mediated diseases with significant unmet need.

Trialynx founder and CEO Angela Schwab continues her conversation with PharmExec and explains the effective ways that AI is being used to tackle common problems with clinical trial design.

In today’s Pharmaceutical Executive Daily, Amgen announces an $840 million acquisition of Dark Blue Therapeutics, GSK enters a multi-year precision medicine collaboration with Helix, and industry leaders examine how workable operating models are reshaping cell and gene therapy commercialization.

FDA’s decision to limit regulations of non-medical grade wearables marks a notable shift toward regulatory restraint in digital health.

Can generics be liable for induced infringement despite carve-outs?

GSK’s multi-year collaboration with Helix signals a push to embed genomics and real-world data into drug development, positioning precision medicine as a core engine for target discovery, clinical design, and long-term portfolio differentiation.

When approaching cell and gene therapies (CGT), investors want to back companies that demonstrate operational foresight. Here are five levers for building a CGT operating model that can tackle the category’s unique commercialization complexities.

Angela Schwab, founder and CEO of Trialynx, discusses the current state of AI in the pharmaceutical industry and why it’s important for companies to demonstrate the true value of their AI-based products.

In today’s Pharmaceutical Executive Daily, Eli Lilly and Nimbus Therapeutics announce a major licensing deal for oral obesity treatments, Hoth Therapeutics expands its intellectual property portfolio with new provisional patents, and Alnylam commits $250 million to expand manufacturing capabilities in Massachusetts.

Pharmaceutical manufacturers must address the question of how exactly does value get created and destroyed inside these organizations and how will AI fundamentally shift that equation?

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing focus on targeted protein degradation.

Nimbus Therapeutics and Eli Lilly expand partnership with a new multi-year research and licensing collaboration aimed at advancing next-generation oral therapies for obesity and metabolic disease.

In the absence of clear regulatory standards, oversight is increasingly being defined through audits, investigations, and enforcement actions by federal regulators and state medical boards rather than prospective guidance.

In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, clears a new therapy to prevent motion-induced vomiting, and Sanofi enters a new antibody discovery collaboration targeting autoimmune disease.